Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Goldman Sachs analyst Rajan Sharma initiates coverage on GSK (NYSE:GSK) with a Neutral rating and announces Price Target of ...
Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers.
Chicago jury rejects woman's claim that Zantac caused her colon cancer. First of thousands of similar lawsuits, companies d...
- Reuters
Sanofi reveals Phase 2 results for rilzabrutinib in moderate-to-severe asthma. High and low doses showed a reduction in asthma ...
Valisure sues GSK accusing the company of hiding cancer risks linked to Zantac, potentially defrauding the U.S. government. Thi...
GSK announced results from phase 3 trials SWIFT-1 and SWIFT-2, showing depemokimab's efficacy and safety in reducing severe...
